pTVG-HP
Phase 2Biologic
pTVG-HP is one of 47 biologic programs targeting Prostate Cancer. It is currently in Phase 2.
3
Indications
7
Total Trials
3
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Glucophage
EMD SeronoPhase 3
Antibiotic
PfizerPhase 3
Gnrh Agonist/antagonist
NNorthwestern University
Phase 3
Piflufolastat F 18
NovartisPhase 3
Antibiotic Prophylaxis
AAssistance Publique - Hôpitaux de Paris
Phase 3
pTVG-HP
UUniversity of Wisconsin, Madison
Phase 2
Trexall
Jazz PharmaceuticalsPreclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Duragesic
CCephalon
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer3 trials
Metastatic Prostate Cancer2 trials
Recurrent1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for pTVG-HP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Wisconsin, Madison